Pfizer has made a new and improved bid to acquire AstraZeneca with an offer worth £69.3 billion pounds ($116.6 billion) or £55 a share – and says this is its best and final offer for the firm.

Pfizer: It is one of the largest and most successful ... Lilly’s stock has risen 25% in the past year. AstraZeneca: It boasts a diversified geographical footprint as well as a product portfolio ...

A small study published Monday found that the COVID-19 antiviral treatment Paxlovid may have use as a treatment for long ...

Analysis of AstraZeneca's market potential, including China and IRA impacts, and the importance of key readouts in 2025 for ...

The latest health news highlights Trump considering an executive order to protect gas stoves, warnings for GSK's and Pfizer's ...

The institute originally began reviewing Lynparza in this setting in 2018 but ended its review due to lack of evidence.

Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased AstraZeneca PLC (“AstraZeneca” or the “Company”) (NASDAQ: AZN) securities between February 23 ...